68Ga-PSMA-11 PET/CT detects prostate cancer at early biochemical recurrence with superior detection rate and reader agreement when compared to 18F-Fluciclovine PET/CT in a prospective head-to-head comparative phase 3 study. Calais, J., Ceci, F., Eiber, M., Gartmann, J., Nguyen, K., Lok, V., Elashoff, D., Grogan, T., Slavik, R., Reiter, R., Rettig, M., Jadvar, H., Bach-Gansmo, T., Savir-Baruch, B., Hofman, M., Nanni, C., Rischpler, C., Thomas Hope11, W. F., & Czernin, J. Journal of Nuclear Medicine, 60(supplement 1):587–587, Soc Nuclear Med, 2019.
bibtex   
@article{calais201968ga,
  title={68Ga-PSMA-11 PET/CT detects prostate cancer at early biochemical recurrence with superior detection rate and reader agreement when compared to 18F-Fluciclovine PET/CT in a prospective head-to-head comparative phase 3 study},
  author={Calais, Jeremie and Ceci, Francesco and Eiber, Matthias and Gartmann, Jeannine and Nguyen, Kathleen and Lok, Vincent and Elashoff, David and Grogan, Tristan and Slavik, Roger and Reiter, Robert and Matthew Rettig and Hossein Jadvar and Tore Bach-Gansmo and Bital Savir-Baruch and Michael Hofman and Cristina Nanni and Christoph Rischpler and Thomas Hope11, Wolfgang Fendler and Johannes Czernin},
  journal={Journal of Nuclear Medicine},
  volume={60},
  number={supplement 1},
  pages={587--587},
  year={2019},
  publisher={Soc Nuclear Med}
}

Downloads: 0